Current status of SRC inhibitors in solid tumor malignancies.
about
How do kinases contribute to tonicity-dependent regulation of the transcription factor NFAT5?A novel 3D fibril force assay implicates src in tumor cell force generation in collagen networksRaf-interactome in tuning the complexity and diversity of Raf function.Novel autophosphorylation sites of Src family kinases regulate kinase activity and SH2 domain-binding capacityRole of ABL family kinases in cancer: from leukaemia to solid tumoursMulti-target drugs: the trend of drug research and developmentThe Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network PerspectiveA Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region.The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review.Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasisPhase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancerBioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancerPhase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.Diacylglycerol kinase α promotes 3D cancer cell growth and limits drug sensitivity through functional interaction with Src.Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation studyNovel Bioluminescent Activatable Reporter for Src Tyrosine Kinase Activity in Living Mice.The Emerging Role of ABL Kinases in Solid Tumors.Proteolysis of EphA2 Converts It from a Tumor Suppressor to an OncoproteinSRC points the way to biomarkers and chemotherapeutic targets.Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancerSrc inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis.SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.Targeting SRC and tubulin in mucinous ovarian carcinoma.Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.Invading one step at a time: the role of invadopodia in tumor metastasis.Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.New treatments for autosomal dominant polycystic kidney diseaseNovel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer.Src signaling pathways in prostate cancer.Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns.Improvement of pyrazolo[3,4-d]pyrimidines pharmacokinetic properties: nanosystem approaches for drug delivery.NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib.Src-dependent phosphorylation of μ-opioid receptor at Tyr(336) modulates opiate withdrawal.Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
P2860
Q26770757-D71925BA-5FEF-485C-8CA2-7B3718DFF82EQ27335593-2AA39662-D4E0-4B89-88EA-D71CF58A0DE8Q27692653-CAC504CA-DC80-491E-8DE7-76ABDF85327CQ28115874-DE1EED8E-C588-4B1F-9BDD-A8C06E44C369Q28396643-5C6894B5-3731-4423-8811-705491ED286BQ28480888-E39FCF10-A9FE-4285-876B-EE3FD06A84E5Q28553277-417B4A9D-69AE-49E9-BAD4-BD8354B13E33Q30009284-8AB426B4-D3AC-4B49-9061-78E7F9410018Q30248645-D5F9EA1E-FEB5-4307-8701-D67372AFCDBEQ30416923-044880D4-0759-405B-BE8A-FA5A42DED184Q30679405-50DAC4ED-78A5-402B-8F13-9002FC9F1C99Q33405571-40EBE2D0-9B2C-4E7D-9D18-79E0EBEC82A6Q33884709-B758BF22-E812-4840-AD72-B50A1DC1316EQ33940893-278B735D-0E1F-489F-804A-CC96212E6BE1Q34295621-DB640493-4B4A-40DB-9552-11F1AFB86283Q34480200-3FA824A4-1451-4A17-BF31-334DF7666740Q34654588-FB0E0CD0-8B23-4771-A838-D740E58B2378Q34658293-BB8CE5FF-C91C-4139-8844-C33C38C0E13BQ35945748-918CB364-1BB5-4586-A6EE-39E10E4A39A4Q36347666-B7BE050D-55EF-47F2-9F91-DD09ECEAEFF4Q36380708-0BE11461-CAE9-4317-93B3-1C3A38341CA1Q36443406-E184106F-7D09-4838-A33B-B53B252DA091Q36530668-81F2F5E9-D82F-4369-AD67-5CB835FCC6B8Q36777632-F7F1AB42-B10D-4ED1-A708-AF2FA8C19536Q37327588-F78B9DA2-35A6-409B-832E-EF5EFE92EDE8Q37362851-BDDB6FA7-5A5C-4CC0-81DB-79A99E75F8ABQ37366157-2AB22712-721E-4C49-B3D5-B9B1A09CAA68Q37625252-DCF8B0FB-B4CF-4227-BF8E-37EB55411C0DQ37672635-C1FB74C7-E9F3-492C-8535-C58830A39F90Q37684642-9F35A76F-BCDB-4692-817A-BBCAE3515A1CQ37698857-81006A0E-3793-4DA1-9A6C-4F4AC45FDC32Q38099698-E222945E-B1DC-4602-BDC1-AE9FEFFEE948Q38167808-385B39A9-7BEE-434A-AFF9-B0E198345B78Q38187565-7A2BB0BB-40BC-4EEC-BA25-40A24E20FB39Q38269966-D3AB7B47-D638-48D0-BE33-35ABA9364DA0Q38582337-83DC0F16-E68C-4C53-86D6-25EFB7F8582DQ38631124-31C60D95-364E-4966-BD7E-4AA36066AAB1Q38640572-CC7D833B-9A1B-4784-9E5C-BCA2A5BBC2F8Q38925157-1FDD1F54-59C8-4237-8625-A5538A26F85CQ38999290-023ECF93-72DB-4351-998D-9F46EE9F3C49
P2860
Current status of SRC inhibitors in solid tumor malignancies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current status of SRC inhibitors in solid tumor malignancies.
@en
Current status of SRC inhibitors in solid tumor malignancies.
@nl
type
label
Current status of SRC inhibitors in solid tumor malignancies.
@en
Current status of SRC inhibitors in solid tumor malignancies.
@nl
prefLabel
Current status of SRC inhibitors in solid tumor malignancies.
@en
Current status of SRC inhibitors in solid tumor malignancies.
@nl
P2093
P2860
P1433
P1476
Current status of SRC inhibitors in solid tumor malignancies.
@en
P2093
Lauren N Puls
Matthew Eadens
Wells Messersmith
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0408
P577
2011-04-26T00:00:00Z